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Background: Therapy guidelines recommend speech and language therapy (SLT) as the “gold standard” for
aphasia treatment. Treatment intensity (i.e., ≥5 hours of SLT per week) is a key predictor of SLT outcome. The
scientific evidence to support the efficacy of SLT is unsatisfactory to date given the lack of randomized controlled
trials (RCT), particularly with respect to chronic aphasia (lasting for >6 months after initial stroke). This randomized
waiting list-controlled multi-centre trial examines whether intensive integrative language therapy provided in
routine in- and outpatient clinical settings is effective in improving everyday communication in chronic
post-stroke aphasia.
Methods/Design: Participants are men and women aged 18 to 70 years, at least 6 months post an ischemic or
haemorrhagic stroke resulting in persisting language impairment (i.e., chronic aphasia); 220 patients will be screened
for participation, with the goal of including at least 126 patients during the 26-month recruitment period. Basic
language production and comprehension abilities need to be preserved (as assessed by the Aachen Aphasia Test).
Therapy consists of language-systematic and communicative-pragmatic exercises for at least 2 hours/day and at least
10 hours/week, plus at least 1 hour self-administered training per day, for at least three weeks. Contents of therapy
are adapted to patients’ individual impairment profiles.
Prior to and immediately following the therapy/waiting period, patients’ individual language abilities are assessed via
primary and secondary outcome measures. The primary (blinded) outcome measure is the A-scale (informational
content, or ‘understandability’, of the message) of the Amsterdam-Nijmegen Everyday Language Test (ANELT), a
standardized measure of functional communication ability. Secondary (unblinded) outcome measures are language-
systematic and communicative-pragmatic language screenings and questionnaires assessing life quality as viewed by
the patient as well as a relative.
The primary analysis tests for differences between the therapy group and an untreated (waiting list) control group
with respect to pre- versus post 3-week-therapy (or waiting period, respectively) scores on the ANELT A-scale.
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Statistical between-group comparisons of primary and secondary outcome measures will be conducted in intention-
to-treat analyses.
Long-term stability of treatment effects will be assessed six months post intensive SLT (primary and secondary
endpoints).
Trial registration: Registered in ClinicalTrials.gov with the Identifier NCT01540383
Keywords: Aphasia, Chronic, Intensive therapy, Outcome, RCT, Recovery, Stroke, Treatment efficacyBackground
Aging populations and higher survival rates in patients
with acute stroke place increasing financial constraints
on the health care system, requiring evidence-based in-
terventions in stroke rehabilitation [1-3]. One of the
most devastating conditions after stroke is aphasia, a dis-
turbance in language function, which affects about 27%
of all stroke patients [4]. About half of the initially af-
fected patients still suffer from aphasia one year after
stroke [5-7]. Apart from the emotional burden associ-
ated with aphasia [8], language dysfunction in the post-
acute or chronic phase after a stroke is a major reason
for failure of vocational rehabilitation [9]. Impaired com-
munication ability commonly represents an obstacle to
vocational and professional reintegration, thus incurring
health care costs and losing potential contributors to the
‘social contract’ (i.e., fiscal payments) [10].
Therapy guidelines recommend speech and language
therapy (SLT) as the ‘gold standard’ for aphasia treat-
ment. Treatment intensity (i.e., ≥5 hours of SLT per
week) appears to be a key predictor of SLT outcome
[11]. The scientific evidence to support the efficacy of
SLT is unsatisfactory to date [12] given the lack of ran-
domized controlled trials (RCTs), particularly with re-
spect to chronic aphasia (lasting for >6 months after the
initial stroke). Even though recent evidence-based re-
views support the efficacy of intensive aphasia therapy
[2,13], the available evidence has not yet led to increased
referrals for aphasia patients. This state of affairs may in
part be due to a lack of high-quality RCTs with positive
outcome as well as to a failure to administer a functional
outcome measure. In the age of evidence-based medicine,
however, there is a growing demand that SLT should be
evidence-based and that outcomes should be operationa-
lized with respect to participative gains [14,15].
Furthermore, motivated by the World Health Or-
ganization (WHO) guidelines regarding more patient-
centred, outcome-oriented therapy schemes (International
Classification of Functioning, Disability and Health [16]),
aphasia rehabilitation facilities increasingly apply an inte-
grative naturalistic therapy approach [17-19]. This integra-
tive approach, which may be described as the agreed best
practice, consists of both language-systematic and com-
municative-pragmatic exercises as well as a combinationof one-on-one and group therapy settings. In addition, pa-
tients are often encouraged to supplement the gains of
intensive therapy with self-administered computerized
language exercises.
The efficacy of intensive SLT under such ‘natural’ ther-
apy conditions, however, has never been investigated in
persons with chronic aphasia, although there is mount-
ing evidence consistent with the assumption that SLT is
efficacious when treatment intensity is sufficiently high.
Specifically, aphasia therapy has been shown to be effica-
cious when treatment is provided for at least 5 hours per
week for a period of several weeks [11]. A 2003 syste-
matic review found that therapy studies which reported
positive outcomes had administered an average of 8.8
hours of therapy per week [13]. The authors of this re-
view noted, however, that only few of the studies in-
cluded were rated to be of good quality; the majority of
the studies were either of fair quality or did not fulfil
basic quality criteria (such as randomizing participants
to conditions). Since then, several empirical studies on
SLT in post-acute/chronic aphasia have corroborated the
assumption that short periods of intensive SLT (i.e., two
weeks duration with several hours of SLT daily) signifi-
cantly enhance linguistic functions even in the chronic
stage after a stroke [20,21], with excellent long-term sta-
bility of therapy outcome [21,22]. However, the number
of participants in these studies was relatively small;
numbers ranged from 12 [21] to 28 [20] individuals with
aphasia. Furthermore, apart from questionnaires asking
patients and relatives to indicate the estimated level of
communicative abilities, primary outcome measures in
these studies were operationalized as changes in scores
of standardized language test batteries. These types of
outcome measures have been increasingly criticized
because they do not reflect potential gains in every-
day communicative language functions.
In the past two years, several RCTs with large numbers
of participants have used primary outcome measures fo-
cused on functional communication ability [23-25]. In
all of these trials, treatment started within the period of
spontaneous remission after the initial stroke. Laska
et al. initiated treatment sessions within two days after
stroke, and administered 3.75 hours of therapy per
week for a period of 21 days [25]. Therapy focused
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After three weeks, no difference was found on the
Amsterdam-Nijmegen Everyday Language Test (ANELT)
between the treatment group and an untreated control
group. Bowen et al. administered on average 18 hours
total of agreed best practice of communication therapy
over a period of up to four months (i.e., on average less
than 2 hours per week) [23]. At six months post onset, no
difference in a functional outcome measure was found
between the treated group and a control group re-
ceiving social contact by contracted “visitors” with a
similar frequency.
Compared to the significant improvements found in
the studies administering intensive therapy with a fre-
quency of at least 1 hour per day, the latter findings
strongly suggest that the negative findings may partly
have been due to the fact that therapy was administered
with a frequency below the minimum of 5 hours per
week recognized as being efficacious [13]. Thus, for pa-
tients with stroke-induced chronic aphasia, an evaluation
of the efficacy of intensive integrative, systematic therapy
with respect to everyday communication ability is ur-
gently needed.
Objective
This prospective randomized controlled endpoint-blinded
trial aims to examine whether, in chronic aphasia, the in-
tegrative approach to intensive language and communica-
tion therapy translates into functional improvements ofTable 1 List of participating institutions and contact person (
Participating centre (location in italics)
Max-Planck-Institut für Kognitions- und Neurowissenschaften Leipzig und Tag
(A. Villringer, H. Obrig, F. Regenbrecht)
Brandenburg Klinik Bernau Waldfrieden (M. Jöbges, Maria Bley)
Neurologische Klinik, Lehr- und Forschungsgebiet Neurolinguistik, Universität
Städtisches Klinikum München Bogenhausen, Klinik für Neuropsychologie (G.
Aphasiestation der Neurologischen Klinik Bad Aibling am Standort Rosenheim
St. Mauritius Therapieklinik Meerbusch (S. Knecht, B. Gröne)
Median-Klinik Grünheide, Berlin (J. Knauss, K. Bölle, R. Baake)
m&i Fachklinik Enzensberg (U. Steller, R. Sudhoff, K.-J.Schlenck)
m&i Fachklinik Bad Liebenstein (G. Pfeiffer, E. Schillikowski)
Aphasiezentrum Josef Bergmann, Vechta (F.-J. Ferneding, K. Billo, H. Hoffmann
Logopädisches und interdisziplinäres Behandlungszentrum für Intensivtherap
Asklepios Neurologische Klinik Falkenstein (K. Krakow, B. Wilde)
Wicker-Klinik Bad Homburg v.d.H. (F. Reinhuber, C. Berghoff)
Akademische Praxis für Sprachtherapie/Neurologische Praxis Aschaffenburg (I.
m&i Fachklinik Herzogenaurach (W. Schupp, C. Sous-Kulke)
Gräfliche Kliniken Moritz Klinik Bad Klosterlausnitz (D. Bätz, F. Hamzei)
MediClin Klinikum Soltau (A. Meyer, Katja Schulz)everyday communication as well as improved health-
related quality of life.
The principal research question is two-fold: (i) how
effective is intensive integrative (i.e. combined language-
systematic and communicative-pragmatic) language
therapy, as currently administered in German in- and
outpatient aphasia rehabilitation facilities, in impro-
ving everyday communication in post-acute/chronic
post-stroke aphasia; and (ii) to what degree are these
improvements maintained over a period of 6 months?
Methods/Designa
The current trial uses a prospective randomized open
blinded end-point (PROBE) design [26] with a waiting-
list control group. The trial was approved by the Ethics
Committee of the Charité – Universitaetsmedizin Berlin,
Germany (No. EA1/234/11, approval received in Decem-
ber 2011). In addition, the study has the approval of the
local ethics committees of the respective German federal
states in which the 17 participating neurorehabilitation
centers are located (Table 1).
Study population
Inclusion criteria
 Non-haemorrhagic or haemorrhagic cortical,
subcortical, or subcortico-cortical stroke;
 Presence of aphasia for at least 6 months;
 Age between 18 years and 70 years;i.e., Centre coordinator)
Centre coordinator
esklinik für Kognitive Neurologie Frank Regenbrecht
Maria Bley
sklinikum Aachen (C. Werner, K. Halm) Katja Halm
Goldenberg, R. Glindemann, W. Ziegler) Ralf Glindemann
( E. König, F. Müller, G. Klingenberg) Gudrun Klingenberg
Berthold Gröne
Regina Baake
Klaus-Jürgen Schlenck
Eva Schillikowski
) Kathrin Billo
ie Lindlar (V. Middeldorf, S. Krüger, T. Keck) Tina Keck
Barbara Wilde
Carla Berghoff
Maser, W. Hofmann) Ingeborg Maser
Christa Sous-Kulke
Anke Oertel
Katja Schulz
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 A score of at least 1 (between 0 and 5) on the
communicative ability scale of the Aachen Aphasia
Test/AAT [27];
 Less than the maximum score of 10 error points on
the first of five subtests of the AAT Token Test
(securing basic comprehension of spoken
instructions).
In cases in which potential participants have been
appointed a guardian, the guardian’s written approval to
participation in the trial is required in addition to the
signature of the patient. Further, if the patient has a
guardian, the attending physician is asked to attest a pa-
tient’s ability to decide for him- or herself whether or
not he or she wishes to participate.
Exclusion criteria
 No verifiable aphasia according to the criteria of the
AAT;
 Aphasia due to traumatic brain injury or
neurodegenerative diseases;
 Severe uncontrolled medical problems;
 Severe uncorrected-to-normal visual or auditory
impairment;
 Participation in an alternate intensive intervention
to relieve stroke symptoms during the past four
weeks prior to enrolment.
Therapy
Therapy consists of a combination of language-sys-
tematic and communicative-pragmatic approaches. In
order to tailor therapy to the individual needs of the pa-
tients, we designed specific screening measures by which
the individual severity of impairment across the various
domains of language and communication may be iden-
tified in each patient prior to therapy. These scree-
ning measures examine language-systematic as well as
communicative-pragmatic language functions. Individual
therapy targets are set upon identification of perform-
ance levels in the screening measures. Contents of ther-
apy are determined by a detailed standardized therapy
manual which allows (i) establishment of a therapy plan
tailored to the individual patient’s focus and level of
language impairment(s); and (ii) adaptation of therapy
material and/or therapy methods to the expected im-
provements in linguistic and communicative ability over
the course of therapyb. Participants’ progress is moni-
tored daily, and monitoring results as well as therapy
content are documented by the attending therapists. All
therapists in the participating centres underwent com-
prehensive training with the therapy manual prior to pa-
tient recruitment.Study design
The study design is depicted in Figure 1. The inclusion
of a waiting list control group, intended to control un-
specific effects of language therapy, circumvents the eth-
ical dilemma of withholding potentially efficacious
treatment from patients. After a 3-week waiting period,
the control group receives the same treatment as the ex-
perimental group.
A particular design aspect, namely the repeated test
points t2b and t3b of Figure 1, is due to the heterogen-
eity of current therapy funding by German health funds.
Initial funding is generally granted for 3 to 4 weeks, and
may be extended for up to 7 weeks during the rehabilita-
tion phase for some of the patients. For statistical rea-
sons, we fixed a test point immediately after the 3-week
intensive therapy (i.e., t2 and t3, respectively, in Figure 1)
which includes all patients enrolled in the study. When-
ever a patient’s individual funding period comprises at
least 5 weeks of therapy, testing is repeated at the end of
this patient’s total therapy period (i.e. t2b/t3b in Figure 1).
The additional test point serves to measure further po-
tential improvements beyond the initial 3-week therapy
period. Initial screening, baseline testing, and follow-up
tests are performed by specially trained ‘study assessors’
(SAs), all with long-term experience in diagnosis and
treatment of neurogenic speech and language disorders.
All of the screening measures and tests are scored by the
assessing SAs, and validated by an internal data review
process, except for the primary outcome measure (see
below). The primary outcome measure is evaluated by a
specially trained endpoint committee (8 members) which
is blinded with respect to patient group and time of
assessment.
Outcome measures
Primary endpoint
Mean difference on the ANELT [28] A-scale (under-
standability), operationalized as the difference in scores
between the test point immediately after the 3-week in-
tensive therapy (or waiting) period, and the test point
immediately prior to the initiation of treatment (i.e., the
difference of the scores, i.e., ‘t2’ minus those at test point
‘t1’; Figure 1). The ANELT tests verbal communicative
ability in everyday communicative situations, shows a
high concurrent validity with other standard linguistic
assessment tools and is particularly suitable in the post-
acute/chronic phase after stroke.
Key secondary endpoint(s) (exploratory analysis)
(i) Specially devised screening measures for language-
systematic and communicative-pragmatic communica-
tion ability; (ii) the German version of the Stroke and
Aphasia Quality of Life Scale-39/SAQOL-39 [29]; (iii)
German Version of the Communicative Effectiveness
Figure 1 Trial design.
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scenarios [28]; (v) ratings of the syntactic complexity of
the ANELT scenarios using the AAT scoring system for
spontaneous speech [27]; (vi) ratings of non-verbal com-
munication skills on the ANELT scenarios (based on the
Scenario test [31]).
To minimize practice effects due to repeated testing,
the two parallel versions of the ANELT are alternated
across testing sessions (retest reliability of the ANELT-I
and ANELT-II: r >0.92 for the A-scale, r >0.74 for the
B-scale [32]). Retest reliability of the other secondary
outcome measures relating to quality of life is also satis-
factory (CETI: r = 0.73, SAQOL-39: r = 0.98).Procedure
As part of the informed consent, patients are informed
that the trial comprises an experimental condition and a
waiting list (with a 3 week waiting period) condition. Pa-
tients who agree to participate are randomized to either
the intensive therapy or the waiting list group, stratified
according to centre, by a randomization procedure con-
ducted in a central database by the Institute of ClinicalEpidemiology and applied Biometry at the University of
Tuebingen, Germany.
The outcome of the randomization procedure is com-
municated to the respective head of the SLT unit at each
cooperating centre (Table 1) who is the only person to
be informed about group allocation determined by the
randomization procedure. Thus, the speech therapists
conducting therapy are not informed about group allo-
cation. Depending on their group assignment, patients
either start therapy immediately (experimental group) or
3 weeks after the initial baseline session. The scoring of
the primary endpoint (ratings on the ANELT A-scale)
and the secondary ANELT endpoints is conducted in-
dependently from the therapists and study assessors
performing the pre- and post-therapy assessments. That
is, ANELT scoring is performed by an endpoint com-
mittee consisting of 8 raters, who are experienced in
ANELT administration and scoring, and who have been
specially trained to perform ANELT scoring in this trial.
ANELT scorers are not involved in any other aspect of
the trial in order to keep them blinded to group allo-
cation (experimental, waiting list) and testing session
(baseline or follow-up). Scoring of the ANELT is based
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assessors. Each recording of an ANELT test is inde-
pendently evaluated by two members of the endpoint
committee; across the eight raters, the distribution of
ANELT recordings for each patient follows a pseudo-
randomized strategy.Power calculation
Sample size calculation was conducted for the compari-
son of mean change in ANELT A-scale score from t1
(baseline) to t2 (after 3 weeks of therapy or waiting) be-
tween the intensive language therapy group and the
waiting list group (Figure 1). As a minimum difference
of 8 points on the ANELT A-scale is considered clinic-
ally significant [32], group sample sizes of 63 were speci-
fied for each group in order to achieve 90% power to
detect a difference of 10 points in the improvement of
the mean ANELT A-scale score between the intensive
treatment group after 3 weeks of intensive therapy and
the waiting list group (difference of 1 point after 3 weeks
of waiting), assuming a standard deviation for the diffe-
rence in the ANELT A-scale score between t2 and t1 of
14 (10 for the waiting list group; Figure 1). Sample size
was calculated for a two-sided Mann-Whitney test with
significance level (alpha) of P <0.05. Assuming a patient
non-participation rate of 25% prior to official study in-
clusion by randomization (for example due to the pres-
ence of exclusion criteria or no therapy funding by the
respective sickness fund), 2 × 84 = 168 patients have to
be recruited. The assumption of non-parametrical tes-
ting is rather conservative and the actual power will be
larger if parametrical testing is possible.Statistical analyses
Analyses of primary and secondary endpoints will be
performed in the (intention-to-treat) ITT population
consisting of all randomized patients who received at
least one day of therapy, or were at least one day on the
waiting list. If data are normally distributed, parametrical
methods will be used. The primary analysis will test for
differences between the therapy group and the untreated
(waiting list) control group with respect to the mean
change (relative to baseline performance at the test point
prior to the instantiation of therapy) on the ANELT A-
scale at the test point immediately following the 3-week
intensive therapy (or respective waiting) period. As op-
posed to the comparison group, which is not expected
to demonstrate a clinically significant change between
the two baseline assessments prior to SLT on the ANELT
A-scale scores, the therapy group on average is expected
to show a clinically significant improvement between the
two test points. In the following paragraphs, statistical
analyses are explained in more detail.Primary analysis
The primary endpoint will be evaluated at baseline (t1)
and immediately after 3 weeks of intensive therapy/
waiting period (t2), by a statistical between-group com-
parison of the ANELT A-scale (ANCOVA) in an ITT de-
sign and with methods of multiple imputation taken into
account. We expect that monotone missing data pat-
terns will be observed (as described in [33]) and tech-
niques appropriate for this situation will be applied. As a
sensitivity analysis, the last-observation-carried-forward
method will be applied.
Based on prior studies, we expect a therapy-induced
improvement on the ANELT A-scale of M = 10 points
(SD = 14) from baseline to immediately after 3 weeks of
intensive therapy in the intensively treated group. For
the waiting list group, we expect a change of M = 1 point
(SD = 10) from baseline (t1) to the end of the 3-week
waiting period (t2).
Secondary analyses
Performance on the ANELT A-scale will also be eval-
uated at baseline (t1) and immediately after 3 weeks of
intensive therapy/waiting period (t2), by a statistical
between-group comparison of the ANELT A-scale
(ANCOVA) in a treated-per-protocol design. In patients
who are granted an extension beyond 5 weeks of inten-
sive language therapy by their respective sickness fund,
performance on the ANELT A-scale from pre to post
therapy will again be evaluated immediately after the
total intensive therapy period (i.e., 5–7 weeks after the
baseline assessment = t2b), by a statistical between-
group comparison of the ANELT A-scale (ANCOVA) in
an ITT design where the last observation will be carried
forward. This design feature is required due to the cur-
rent heterogeneous therapy funding practices by the
sickness funds. Initial funding is generally granted for 3
weeks, and for some patients (about 20%) extended for
up to 7 weeks. The decision about the extension is made
after rehabilitation therapy has started. Therefore, total
duration of therapy cannot be planned a priori. Second-
ary endpoints (language-systematic and communicative-
pragmatic screening measures; German version of the
SAQOL-39, German Version of the CETI, ANELT B-
scale as well as syntactic and non-verbal communication
ratings) will be analysed in analogy to the primary ana-
lysis at baseline (t1) and immediately after 3 weeks of
intensive therapy/waiting period (t2), by a statistical
between-group comparison (ANCOVA) in an ITT de-
sign. Where applicable, the secondary endpoints will
again be evaluated after a variable therapy extension for
up to 7 weeks total therapy (t2b) in a subgroup of pa-
tients (cf. secondary analysis of the ANELT A-scale).
Maintenance of therapy gains will be evaluated 6 months
after termination of the first 3 weeks of intensive therapy
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t1, respectively. The amount of outpatient therapy pro-
vided between t2/t2b and t4 will be statistically con-
trolled by covariate analyses.
Waiting list control group
In analogy to the experimental group, therapy effects
will be analysed immediately after 3 weeks of intensive
therapy (t3). We expect a mean change of M = 10 after
intensive therapy (comparisons of t1 and t3). We expect
that therapy effects will be comparable to those of the
experimental group. Outcome data of the waiting list
group thus also serve to replicate the effect of intensive
language therapy under routine clinical conditions. For
control group patients who are granted more than 3
weeks of intensive language therapy, performance on the
ANELT A-scale will again be evaluated immediately after
the total period of therapy (i.e., 5–7 weeks of therapy,
depending on the extension granted = t3b) in analogy to
the experimental group. Again, we expect therapy effects
to be comparable to those of the experimental group
after 5–7 weeks of therapy. Maintenance of therapy
gains will be evaluated 6 months after termination of the
first 3 weeks of intensive therapy (t4, long-term out-
come) by statistical comparisons with t1, respectively.
Taking into account that age, gender, time after stroke
onset, aphasia type (fluent, non-fluent), aphasia severity
(based on the AAT profile score), the total hours of
therapy provided, type of stroke (cortical strokes with or
without subcortical involvement), the amount of therapy-
concomitant self-administered language practice (e.g.
computer-aided practice), and medication and physio-
and neuropsychological therapies might influence func-
tional outcome, these factors will be included in a
multivariate analysis with variable selection. No adjust-
ment for multiplicity of testing will be provided. All ana-
lyses except for the primary analysis of the primary
endpoint thus will not be strictly confirmatory.
Trial status
The trial started in February 2012; patient recruitment
started April 1, 2012. The last patient will be included
on June 1, 2014 (last 6-month follow-up on January 31,
2015).
Endnotes
aA written version of a talk about the study, held at
the 2013 Annual Meeting of the German Society of
Speech-, Language-, and Voice Pathology by CB, will be
published as part of a national German conference pro-
ceeding in the journal ‘Sprache-Stimme-Gehör’.
bThe German therapy manual developed for FCET2EC
is intended for publication (Eds.: Grewe, Baumgaertner
& Springer†).Abbreviations
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